A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of MNRP1685A, a Human IgG1 Antibody, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Incidence and nature of dose-limiting toxicities (DLTs)
Length of study
No
Rainer Brachmann, M.D.
Study Director
Genentech
United States: Food and Drug Administration
ANP4509g
NCT00747734
September 2008
Name | Location |
---|